Hikma Pharmaceuticals (LON:HIK) Shares Pass Above 200-Day Moving Average of $1,889.51

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,889.51 ($24.06) and traded as high as GBX 2,016.16 ($25.67). Hikma Pharmaceuticals shares last traded at GBX 1,994 ($25.39), with a volume of 172,112 shares.

Analyst Ratings Changes

HIK has been the topic of a number of research reports. Barclays reiterated an “equal weight” rating and issued a GBX 2,000 ($25.47) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 7th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 ($25.47) price target on shares of Hikma Pharmaceuticals in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,050 ($26.10).

Hikma Pharmaceuticals Price Performance

The stock’s fifty day moving average is GBX 1,916.62 and its 200-day moving average is GBX 1,891.01. The stock has a market capitalization of £4.34 billion, a PE ratio of 2,922.39, a P/E/G ratio of 2.38 and a beta of 0.44. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Riad Mishlawi acquired 736 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were acquired at an average cost of GBX 1,979 ($25.20) per share, with a total value of £14,565.44 ($18,547.61). Insiders own 30.62% of the company’s stock.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.